Meta-analysis of 5 randomized controlled trials including 2,317 patients with melanoma concluded that combination therapy with BRAF inhibitor and MEK inhibitor was associated with a higher risk of pulmonary embolism (RR: 4.36; 95% CI: 1.23-15.45; P = 0.02) compared with BRAF inhibitor monotherapy. Here, BRAF is linked to pulmonary embolism.